Dexrazoxane, classified under bisdioxopiperazine compounds, serves as a water-soluble analog of the iron chelator ethylenediaminetetraacetic acid (EDTA). It is primarily used to mitigate or prevent ...

地雷佐生是一种细胞保护药物，用于预防和改善与转移性乳腺癌阿霉素治疗相关的心肌病。 每瓶右雷佐生 250mg、500mg；重构和稀释后用于静脉输注。 地雷佐生是 EDTA 的环状衍生物，可轻易穿透细胞膜。地雷佐生发挥心脏保护作用的机制尚不完全清楚。 【右雷佐 ...

地雷佐生是一种细胞保护药物，用于预防和改善与转移性乳腺癌阿霉素治疗相关的心肌病。 每瓶右雷佐生 250mg、500mg；重构和稀释后用于静脉输注。 地雷佐生是 EDTA 的环状衍生物，可轻易穿透细胞膜。地雷佐生发挥心脏保护作用的机制尚不完全清楚。 【右雷佐 ...

The average cumulative anthracycline dose was 198.1±99.5 mg/m 2. Twenty‐four patients received anti‐HER2 (human epidermal growth factor receptor 2) therapy for breast cancer and no patients received ...

阿霉素（Doxorubicin）治疗肉瘤时存在心脏毒性，右丙亚胺（Dexrazoxane）可预防，助力高剂量给药。 阿霉素的应用困境与右丙亚胺的登场 在癌症治疗的广阔领域中，阿霉素一直占据着重要地位，无论是实体肿瘤还是血液系统癌症，它都是治疗方案中的关键药物。

Protective strategies such as dexrazoxane administration, modified dosing schedules, and liposomal formulations can reduce heart damage risk while maintaining cancer-fighting effectiveness.

Timothy F. Murphy, MD SUNY Distinguished Professor Director, CTSI Senior Associate Dean for Clinical and Translational Research Jacobs School of Medicine and Biomedical Sciences, UB Allison Brashear, ...

The field of cardio-oncology has expanded over the past 2 decades to address the ever-increasing issues related to cardiovascular disease in patients with cancer and survivors. There is increasing ...

A public consultation on proposed changes to this document was held from December 2024 to March 2025. Based on the feedback received, this document may change. Learn about the consultation. Drugs ...